Introduction
Alpha 1-antitrypsin (AAT), a 52 kDa serine proteinase inhibitor, is normally secreted from hepatocytes and circulates in the plasma, protecting lung elastin from degradation by neutrophil elastase and related proteases. Deficiency of AAT can lead to pan-acinar emphysema due to destruction of pulmonary interstitial elastin if serum levels fall below 11 m (approximately 800 g/ml).
1,2 In a subset of patients homozygous for the PI*Z mutation, liver disease may also develop, apparently related to polymerization of the mutant protein within the endoplasmic reticulum of affected hepatocytes. [3] [4] [5] AAT deficiency may be a good candidate for gene therapy because of the well-defined therapeutic endpoint and wide therapeutic index. While levels of 800 g/ml seem necessary to avoid the development of clinically significant lung disease, much higher levels (ie 8 mg/ml or more) are observed during acute phase reactions without obvious sequelae. Furthermore, earlier studies of protein replacement indicated that no adverse effects were seen with serum hAAT levels greater than 100-fold above the therapeutic threshold (ie Ͼ80 mg/ml). Clinical experi- ence with protein replacement also indicates a very low likelihood of eliciting immune responses to hAAT in deficient patients. 6 Several vectors have been found to mediate detectable serum levels of hAAT in animal models. [7] [8] [9] [10] [11] First-generation adenoviral vectors have been shown to give therapeutic levels of hAAT. 12 Recently, high capacity adenovirus, 13, 14 and rAAV vectors have demonstrated feasibility of achieving stable levels greater than 800 g/ml. The study by our group indicated that a single i.m. injection of a rAAV-CMV-AAT into murine muscle could mediate stable expression within that range. 15 However, a relatively high dose of rAAV (4 × 10 10 IU) was required. Given the greater than 2000-fold size difference between mice and adult humans, there is a significant incentive to improve the efficiency of this process. Furthermore, the treatment of AAT deficiency-related liver disease will likely be dependent upon transduction of a high percentage of hepatocytes. This is in contrast with gene therapy for lung disease, in which the percent transduction is not critical as long as the end result is a sufficiently high serum level. The current study was designed to test the hypothesis that transduction of murine hepatocytes would be more efficient for expression and secretion of hAAT than skeletal myocytes. Portal vein injection of a rAAV-CB-hAAT vector resulted in stable serum levels of hAAT at a 10-fold lower dose than was required in the previous rAAV muscle injection study.
Results hAAT expression in murine hepatocytes
In order to determine the optimal promoter systems for in vivo studies, a series of rAAV-hAAT constructs utilizing different expression cassettes were constructed (Figure 1 ). These included constructs with the human cytomegalovirus (CMV) immediate-early promoter (C-AT), the human elongation factor 1-␣ promoter (E-AT), or a hybrid CMV enhancer/chicken beta actin promoter/chimeric rabbit beta globin intron expression cassette (CB-AT). A version of C-AT with an intron and without neomycin-resistant gene was also generated (p43C-AT), as was a version of E-AT with a truncated version of the human elongation factor 1-␣ promoter (dE-AT).
Each construct was transfected into the SV40-T antigen-transformed murine hepatocyte cell line, HO15, a generous gift from Dr Janice Chou (National Institutes of Health, Bethesda, MD, USA), and the expression of hAAT was assessed at 48 h using a sensitive and specific ELISA assay on cell medium supernatants. While the other promoters were active, the CB-AT construct showed a clear advantage in this cell line (Figure 2 ), expressing nearly two-fold greater levels than the C-AT contructs and five-fold greater levels than the E-AT constructs. This could not be accounted for solely by the presence of an intron, as indicated by the comparison of the basic C-AT construct with an intron-containing version (p43CAT).
Long-term in vivo expression after portal vein injection in young adult mice
In order to determine the feasibility of achieving stable therapeutic levels (у800 g/ml) of hAAT in the serum, doses of each rAAV-hAAT vectors were injected into the portal veins or tail vein of cohorts of C57Bl/6 female mice. For the E-AT or C-AT vector, cohorts of mice were each injected with 4 × 10 9 infectious units (IU). For the CB-AT vector, two cohorts of mice were injected with either 3 × 10 10 or 4 × 10 9 IU. Once again, the CB-AT vector was the most efficient, expressing sufficient hAAT to maintain serum levels of approximately 1 mg/ml in the high dose group (3 × 10 10 IU per animal) for up to 52 weeks after a single injection (Figure 3 
Construct dE-AT is a derivative of E-AT from a deletion of a silencer region. Construct p43C-AT is similar to CB-AT except for using the CMV promoter instead of the CMV-␤-actin hybrid promoter.

Figure 3 Sustained therapeutic levels of hAAT secreted from mouse liver. Eight-week-old female C57 Bl/6J mice were injected through portal vein (PV) or tail vein (TV) with recombinant AAV vectors. Filled circle, CB-AT (PV), 3 × 10 10 IU per animal (n = 2). Open circle, CB-AT (PV), 4 × 10 9 IU per animal (n = 4). Filled square, E-AT (PV), 4 × 10 9 IU per animal (n = 4). Open square, E-AT (TV), 4 × 10 9 IU per animal (n = 3). Open diamond, C-AT (PV), 4 × 10
9 IU per animal (n = 2). The serum levels of hAAT were monitored by ELISA at the time indicated. Means ± standard deviations are shown for most groups, except for those with n = 2. In the latter groups, means ± ranges are shown.
IU dose, CB-AT still expressed hAAT at or near the therapeutic level (600 g/ml) and was at least 50-fold more efficient than portal delivery of E-AT or C-AT. Interestingly, a cohort of mice treated with E-AT via tail vein injection had levels approximately five-fold lower than a cohort receiving an identical dose by direct portal vein injection. This supports an earlier study in which a 10-fold difference was observed. 16 
Southern blot analysis
In order to determine the number of copies of CB-AT per cell in animals expressing therapeutic serum levels and to determine whether vector DNA was integrated or episomal, we performed Southern blot analysis ( Figure 4 ) on animals 52 weeks after injection. Liver DNA samples were analyzed either without restriction digestion (−), after digestion with an enzyme that does not cut within the CB-AT construct (but does cut elsewhere in genomic DNA, a '0-cutter'), or after digestion with enzymes that cut once or twice within the vector genome ('1-or 2-cutter', respectively; Figure 4a ). In the uncut and 0-cut lanes, low molecular weight (MW) bands (ෂ4.8 and 2.3 kb) were detected with the hAAT probe, indicating the presence of small episomal forms of the vector DNA. These two bands may represent circular supercoiled vector DNA because the sizes did not correspond to those predicted for linear monomer (3.8), or dimer (7.7 kb). Indeed, after digestion with the 1-cut enzyme, both bands had disappeared, while there were fragments of head-to-tail junc- (Figure 4b ), in which additional 0-cut enzymes were used. We also note that the intensity of the head-to-tail junction band in the 1-cut lane was significantly greater than the intensity of the low molecular weight bands in the uncut and 0-cut lanes, suggesting that most of the vector genomes were probably in high MW concatemers.
To estimate the total copies of the vector genome, a 2-cut enzyme (ApaI) was used to release an internal vector DNA fragment (2.3 kb). A density comparison of this band (2.3 kb) with the copy number control plasmid resulted in an average copy number of 25 genomes per cell. This does not necessarily indicate that those genomes are uniformly distributed, however.
Immunostaining of transduced murine livers to detect transgene expression
While the overall efficiency of hAAT expression as a potential therapy for lung disease in AAT deficiency was favorable with the CB-AT vector, the ultimate therapy for AAT-related liver disease will probably require transduction of a high percentage of hepatocytes with molecular therapeutics (eg ribozymes) that down-regulate the mutant protein. Therefore, it is important to determine the percentage of hepatocytes transduced. In order to accomplish this, we performed immunostaining on liver sections from CB-AT-injected mice and uninjected controls using a polyclonal antibody that shows specificity for the human AAT protein over the mouse AAT protein. This was confirmed by staining sections from normal human liver (Figure 5a ), from patients with large accumulations of the PI*Z mutant version of AAT ( Figure  5b) , and sections from PBS-injected control mice ( Figure  5d ).
Human AAT protein expression in the livers of treated mice was confined to a relatively small percentage of hepatocytes, 6.4 ± 2.9% by morphometric analysis (Figure  5c , ±s.d.). Transgene immunoreactivity was seen on a patchy basis throughout the hepatic lobule, but seemed to be most prevalent around portal tracts, and to a lesser extent, around central venules. The combination of this analysis with the Southern blot data indicates that a small number of cells each contain an average of 390 copies per cell, to yield an overall copy number average of 25 per cell over the whole liver. We also noted that there was no indication of an inflammatory response or any other histological abnormalities in the liver or other tissues (data not shown).
In order to confirm independently the distribution of transgene expression with a marker whose detection could not be confused with that of an endogenous protein, we performed additional studies with mice injected with doses of a rAAV-CB-GFP vector (UF11), at the same dose as that used for the CB-AT studies. Immunostaining with an anti-GFP antibody once again revealed a scattered distribution of positive hepatocytes, with the overall transduction rate of 3.3 ± 2.7% (Figure 6, ±s.d.) . Once again, there was no histologic evidence of liver toxicity.
Discussion
The data presented here confirm that portal vein delivery of a rAAV vector results in efficient and stable transgene expression. More specifically, stable serum levels of hAAT that would be therapeutic in a human can be maintained for 1 year after a single injection of rAAV-hAAT in mice. The efficiency of this process appears to be greater than that seen with intramuscular delivery, where 10-fold higher doses were required to achieve similar effects. 15 These results are similar to those shown by Snyder et al, for human factor IX, 17 and by other groups. 18 The level of hAAT expression from CB-promoter in this study is much higher than that in a previous report. 19 The difference between the studies may reflect the higher dose used in our experiments. Our studies also indicated that a moderately high overall copy number of rAAV genomes were accounted for by a limited percentage of hepatocytes, similar to results reported by Miao et al. 20 The copy number of vector genomes (25 per cell) in the liver was much higher than that reported by others. 17 This difference may also reflect the increased dose of vector. The potential utility of this form of therapy has been borne out by the protein replacement therapy experience, which has proved the concept of ectopic delivery of AAT. It is important to note that the clinical experience with hAAT protein replacement indicates that it is safe and non-immunogenic. [21] [22] [23] While this mode of gene delivery may be very useful as therapy for their lung disease, the minority of patients who also suffer from liver disease will require a higher percentage of hepatocytes to be transduced. A recent study showed that the vast majority of hepatocytes took up rAAV vector, but only a small and changing subpopulation of hepatocytes were permissive for stable transduction. 24 It is not clear whether or not this is an inherent limitation of rAAV-mediated hepatocyte transduction.
The advantage of the CB promoter over other promoters is also consistent with other reports using rAAV vectors delivered systemically or by other routes. 19 Several reports have indicated that the CMV immediateearly promoter is prone to silencing, 9,17 while endogenous promoter elements are not. 25, 26 In particular a study by Guo et al 26 indicated that the EF promoter had much higher stable levels of expression than the CMV promoter. Another recent study by Virella-Lowell et al 27 indicated that in the murine lung the CMV promoter was rapidly silenced, while the CB promoter remained active for many months.
One concern about the approach described here is the potential for inducing innate or acquired immune responses that could be toxic to the host and/or limit the level or duration of transgene expression. In the current study, large doses of rAAV were administered to the portal circulation without any detectible toxicity by histopathologic examination. This is in contrast to the experience with Ad, which induces a proinflammatory cytokine response that can result in severe toxicity. This finding is quite consistent with the rAAV experience in other organs, which indicated a total absence of dose-related inflammatory toxicity. 15, 28, 29 Nonetheless, careful monitoring for signs of local or systemic inflammation should be incorporated into future preclinical or clinical trials.
Previous studies have shown that rAAV genomes gradually integrate into the host cell genome in the murine liver. 16, 20 By comparison, our results showed that high MW episomal concatemers of AAV vectors persisted in liver for a prolonged period. These observations do not exclude the presence of integrated forms of AAV. Indeed, a significant amount of vector signal shifted into a heterogeneous smear migrating faster than the high MW concatemer band after digestion with the 0-cutter. This probably represents the integrated forms (Figure 4b). Our results also showed that small circular episomal forms of rAAV vector were detectable 1 year after vector transduction. We have recently observed similar episomal forms in muscle (unpublished data). The contribution of different forms of the rAAV genome to transgene expression will require further investigation.
Materials and methods
Vector construction and production The C-AT and E-AT vectors were described previously. 15 The dE-AT construct was derived from E-AT by deletion of the potential silencer (352 bp between SacII sites). 30 The p43C-AT plasmid was constructed by insertion of the hAAT cDNA into an AAV-vector plasmid (p43), which contains the CMV promoter, intron and poly (A) sequences. The p43CB-AT was derived from p43C-AT by replacement of CMV promoter with CMV/chicken ␤-actin hybrid promoter sequences. Recombinant AAV vectors, C-AT, E-AT, CB-AT were packaged and purified as described previously. 15, 31 The physical titers of vector preparations were assessed by quantitative competitive PCR and dot blot analysis, and the biological titers were assessed by infectious center assay. The ratios of particles to infectious units (IU) ranged from 20 to 50. All vector Gene Therapy preparations were free of any detectable wtAAV, as indicated either by physical particle or IU measurements.
Cell culture and plasmid transfection
The SV40-T antigen-transformed murine hepatocyte cell line, HO15 (from Dr Janice Chou) was grown in Dulbecco's modified Eagle's medium (DMEM; Mediatech, Herndon, VA, USA) supplemented with 10% FBS. For transfection, cells were seeded and cultured in six-well plates (2 × 10 5 cell per well) with 2 ml of growth medium overnight. Five micrograms of plasmid DNA were transfected in each well with transfection reagent, LipofectA-MINE (Life Technologies, Gaithersburg, MD, USA). Two days after transfection, medium was collected and analyzed for hAAT using the ELISA assay described below.
Animals and portal vein injection
Eight-week-old female C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA) and handled as approved by the University of Florida Animal Care Committee. For tail vein injection, animals were anesthetized by methoxyflurane (Metofane, PitmanMoore, Mandelein, IL, USA) inhalation and injected with 100 l aliquots of either a rAAV vector or PBS. For portal vein injection, all animals were anesthetized with 2-2-Gene Therapy 2,tribromoethanol (0.5 mg/g i.p.) (Sigma-Aldrich, St Louis, MO, USA). A ventral midline abdominal incision was made into the peritoneal cavity and the portal vein was exposed. AAV vectors or PBS were administered into the portal vein using a 30-gauge needle cemented to a capillary pipette and driven by air pressure via rubber tubing and a Drummond self-locking, double-layer 0.8 m filter. Hemostasis was achieved by application of a small piece of gel-foam directly on to the portal vein. Surgeries were performed on a thermo-regulated operating board designed to maintain a temperature of 37°C and routinely lasted 10 min. For monitoring hAAT expression, serum samples were obtained via tail vein from the animals injected with rAAV-AAT vectors or PBS under metofane sedation. The time-points for obtained serum are indicated in Figure 3 .
Determination of serum hAAT
The level of human AAT in the cell culture medium or in mouse serum was determined by enzyme-linked immunoassay (ELISA). Microtiter plates (Immoulon 4; Dynex Technologies, Chantilly, VA, USA) were coated with 100 l of goat anti-hAAT (1:200 diluted; Sigma Immunochemical, St Louis, MO, USA) in Voller's buffer overnight at 4°C. Duplicate standard curves (hAAT; Sigma Immunochemical) and serially diluted unknown samples were incubated in the plate at 37°C for 1 h. After blocking with 3% bovine serum albumin (BSA), a second antibody, rabbit anti-hAAT (1:1000 diluted, Roche Molecular Biochemicals, Indianapolis, IN, USA) was reacted with the captured antigen at 37°C for 1 h. A third antibody, goat anti-rabbit IgG conjugated with peroxidase (1:800 diluted; Roche Molecular Biochemicals) was incubated at 37°C for 1 h. The plate was washed with PBSTween 20 between reactions. After reaction with the substrate (o-phenylenediamine, Sigma Immunochemical), plates were read at 490 nm on an MRX microplate reader (Dynex Technologies).
DNA isolation and Southern blot analysis
For isolation of DNA, mouse liver was minced and incubated in digestion buffer (100 mm NaCl, 10 mm Tris-Cl, pH 8, 25 mm EDTA, pH 8, 0.5% SDS, and 200 g/ml proteinase K) with shaking at 50°C, overnight. Five m NaCl was added to a final concentration of 200 mm. The lysate was extracted twice with buffer-saturated phenol (pH 7.9), twice with phenol:chloroform (50:50), and twice with chloroform followed by ethanol precipitation. To remove the co-precipitated RNA, the DNA solution was incubated with DNase-free RNase at 37°C for 2 h, followed by chloroform extraction and ethanol precipitation. Liver DNA (20 g) was digested with buffer or restriction enzymes (100 units) overnight. Ten units of the same enzyme were then added to the reaction and incubated for 2 h. DNA fragments were separated by electrophoresis on a 0.8% agarose gel and transferred to a nylon membrane (Immobilon-Ny + ; Millipore, Bedford, MA, USA) using a rapid downward transfer system (TURBOBLOTTER; Schleicher & Schuell, Keene, NH, USA). The DNA was cross-linked to the membrane by UV light and baked at 80°C for 2 h. Southern blot hybridization using 32 P-labeled hAAT cDNA was performed at 65°C overnight. 32 Tissue harvest and immunostaining for transgene expression Animals were anesthetized and killed by cervical dislocation. The liver was harvested immediately and placed in appropriate fixatives. The following tissues were then collected for routine histopathological analysis: heart, lungs, kidney, small intestine, pancreas, spleen, brain, gonad and muscle. No inflammation was observed in any of these harvested tissues.
For detection of hAAT, liver tissue from each animal was fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned (4 m). Tissue sections were deparaffinized and rehydrated to water. Following a peroxide blocking step, tissue was blocked with goat serum (Kirkegaard & Perry Laboratories, Gaithersburg, MD, USA). Tissue sections were incubated in antibody solution (1:100 diluted rabbit anti-hAAT; Roche Molecular Biochemicals) at 37°C for 20 min. Detection was carried out using the True Blue peroxidase kit (Kirkegaard & Perry Laboratories). Tissue was counterstained with orcein (Kirkegaard & Perry Laboratories) before dehydration. For detection of GFP, liver tissue from each animal was fixed in buffered formalin. After blocking, tissue sections were incubated in a primary solution of rabbit anti-GFP IgG (1:40 diluted; Molecular Probes, Eugene, OR, USA) at room temperature for 30 min. Sections were then incubated with a biotinylated goat anti-rabbit secondary antibody at room temperature for 30 min followed with peroxidase-conjugated ABC reagent (Vector Laboratories, Burlingame, CA, USA) at room temperature for 30 min. Histochemical detection of peroxidase activity was performed using diaminobenzidine (DAB)/Nickel solution (Vector Laboratories). Tissue was counterstained with 0.05% fast green before dehydration. All sections were permanently mounted with permount. Semiquantitative assessment of the percentage of parenchymal involvement was based on rigorous review of the randomly selected fields as previously described. 33 
